Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)

Daily Sleep Interference Scale (DSIS) Score

Change from baseline in the weekly mean of the Daily Sleep Interference Scale (DSIS) scores. The DSIS asks participants to ''Select the number that best describes how much your pain has interfered with your sleep during the past 24 hours.'' Response options for the DSIS range from 0 (did not interfere with sleep) to 10 (completely interfered with sleep/unable to sleep due to pain).

Time frame: Week 12

Patient Global Impression of Change (PGI-C)

Number of subjects 'much improved' or 'very much improved' on Patient Global Impression of Change (PGI-C)

Time frame: Week 12

Number of Subjects Achieving ≥30% Pain Reduction

Number of subjects achieving ≥30% pain reduction from baseline in the weekly mean NRS average pain intensity related to DPN

Time frame: Week 12

Number of Subjects Achieving ≥50% Reduction

Number of subjects achieving ≥50% reduction from baseline in the weekly mean NRS average pain intensity related to DPN

Time frame: Week 12

Norfolk Quality of Life Questionnaire - Diabetic Neuropathy (QOL-DN) Score

Change from baseline in the Norfolk Quality of Life Questionnaire - Diabetic Neuropathy (QOL-DN) score. The QOL-DN is a 47 item subject reported questionnaire. Scores range from 0-126, and lower scores indicate improved quality of life.